Abstract
BackgroundCurrently, FDA-approved adjuvant immunotherapies are not approved for patients with stage IB–IIA cutaneous melanoma (CM), and this group is not recommended for asymptomatic surveillance imaging.1 However, patients with stage IB-IIA...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have